SavedAdd your journal

Journals / Retina-Vitreus / 2020 / Cilt: 29 - Sayı: 4

Nivolumab-Related Unilateral Panuveitis in a Patient with Metastatic Malignant Melanoma

Ziya AYHAN
Sadettin USLU
Sefik Can IPEK
Sinan UNAL
Fatos ONEN
Isil SOMALI
Ali Osman SAATCI
Pages
340–344
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We aimed to emphasize the need for the careful review of systemic disease history and the drugs used in patients diagnosed with uveitis and to increase awareness of clinicians regarding potential ocular side effects of new generation anti-cancer drugs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Nivolumab is one of the new generation anti-cancer drugs used in the treatment of metastatic malignant melanoma, which acts by stimulating the immune system.
📊
Key Findings & Data:Unilateral panuveitis was diagnosed in the left eye of 45 years-old man who was on nivolumab treatment for metastatic cutaneous malignant melanoma and presented with anterior uveitis, vitritis and macular edema.
💡
Conclusion & Impact:We aimed to emphasize the need for the careful review of systemic disease history and the drugs used in patients diagnosed with uveitis and to increase awareness of clinicians regarding potential ocular side effects of new generation anti-cancer drugs.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Nivolumab is one of the new generation anti-cancer drugs used in the treatment of metastatic malignant melanoma, which acts by stimulating the immune system. Unilateral panuveitis was diagnosed in the left eye of 45 years-old man who was on nivolumab treatment for metastatic cutaneous malignant melanoma and presented with anterior uveitis, vitritis and macular edema. Nivolumab treatment was discontinued and two intravitreal dexamethasone implants were administered to left eye 4-months interval. The signs and symptoms were improved within 6 months of follow-up. We aimed to emphasize the need for the careful review of systemic disease history and the drugs used in patients diagnosed with uveitis and to increase awareness of clinicians regarding potential ocular side effects of new generation anti-cancer drugs.

🔖

Cite This Article

AYHAN, Z., USLU, S., IPEK, S. C., UNAL, S., ONEN, F., SOMALI, I., SAATCI, A. O. (2020). Nivolumab-Related Unilateral Panuveitis in a Patient with Metastatic Malignant Melanoma. Retina-Vitreus, Cilt: 29 - Sayı: 4, 340–344. https://ajindex.com/articles/307860

References (15)

  1. Abril-Rodriguez G, Ribas A. SnapShot: Immune Checkpoint Inhibitors. Cancer cell.2017; 31:848
  2. Haanen JB, Robert C. Immune Checkpoint Inhibitors. Prog Tumor Res. 2015;42:55-66 3. Tocheva AS, Mor A. Checkpoint Inhibitors: Applications for Autoimmunity. Curr Allergy Asthma Rep.2017; 17:72
  3. Abdel-Rahman O, Oweira H, Petrausch U, et al. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Anticancer Ther.2017; 17:387-94
  4. Dalvin LA, Shields CL, Orloff M, et al. Checkpoint inhibitor immune therapy: Systemic Indications and Ophthalmic Side Effects. Retina.2018; 38:1063-78
  5. Antoun J, Titah C, Cochereau I. Ocular and orbital side-effects of checkpoint inhibitors: a review article. Curr Opin Oncol.2016; 28:288-94
  6. Martins F, Sofi ya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019. 16:563-80 8. Davis JL, Madow B, Cornett J, et al. Scale for photographic grading of vitreous haze in uveitis. Am J Ophthalmol. 2010;150:637-41 9. Cully M. Combinations with checkpoint inhibitors at wavefront of cancer immunotherapy. Nat Rev Drug Discov.2015; 14:374-5
  7. Kottschade L, Brys A, Peikert T, et al. A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Res. 2016; 26:469-80
  8. Psimaras D. Neuromuscular complications of immune checkpoint inhibitors. Presse Med. 2018; 47:253-9
  9. Sood A, Cole D, Abdollah F, et al. Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Curr Urol Rep. 2018; 19:68
  10. Bhatti MT, Salama AKS. Neuro-ophthalmic side effects of molecularly targeted cancer drugs. Eye2018; 32:287-301
  11. Conrady CD, Larochelle M, Pecen P, et al. Checkpoint inhibitor-induced uveitis: a case series. Graefes Arch Clin Exp Ophthalmol.2018; 256:187-91
  12. Makarious D, Horwood K, Coward JIG. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors Eur J Cancer.2017; 82:128-36
  13. Obata S, Saishin Y, Teramura K, et al. Vogt-Koyanagi-Harada Disease-Like Uveitis during Nivolumab (Anti-PD-1 Antibody) Treatment for Metastatic Cutaneous Malignant Melanoma. Case Rep Ophthalmol.2019; 10:67-74
  14. Parker JS, Feagin W, Wang C, et al. Corneal ulceration associated with Nivolumab use. Am J Ophthalmol Case Rep. 2019; 14:26-7
  15. Sun Mm, Levinson R, Filipowicz A, et al. Uveitis in Patien